Hyperfine Inc (HYPR) 2023 Q3 法說會逐字稿

Good afternoon, and welcome to Hyperfine third quarter 2023 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Marissa Bych from Gilmartin Group for introductory disclosures.

下午好，歡迎參加 Hyperfine 2023 年第三季財報電話會議。 （操作員說明）謹此提醒，此通話正在錄音以供重播之用。我現在想將電話轉給吉爾馬丁集團的瑪麗莎·比奇 (Marissa Bych)，以進行介紹性披露。

Great. Thank you for joining today's call. Earlier today, Hyperfine Inc. released financial results for the quarter ended September 30, 2023. A copy of the press release is available on the company's website as well as SEC.gov.

偉大的。感謝您參加今天的電話會議。今天早些時候，Hyperfine Inc. 發布了截至 2023 年 9 月 30 日的季度財務業績。新聞稿的副本可在該公司網站以及 SEC.gov 上取得。

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

在我們開始之前，我想提醒您，管理層將在本次電話會議期間發表聲明，其中包括聯邦證券法含義內的前瞻性聲明，這些聲明是根據美國《私人證券訴訟改革法案》的安全港條款制定的。1995 年。本次電話會議中包含的任何與對未來事件、結果或業績的預期或預測相關的陳述均為前瞻性陳述。

All forward-looking statements, including without limitation, those relating to our operating trends and future financial performance expense management expectations for hiring, training and adoption growth in our organization, market opportunities, commercial and international expansion, regulatory approvals and product development are based upon our current estimates and various assumptions.

所有前瞻性陳述，包括但不限於與我們的營運趨勢和未來財務表現、我們組織中招聘、培訓和採用成長的費用管理預期、市場機會、商業和國際擴張、監管批准和產品開發相關的陳述，均基於我們目前的估計和各種假設。

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.

這些陳述涉及重大風險和不確定性，可能導致實際結果或事件與這些前瞻性陳述預期或暗示的結果或事件有重大差異。因此，您不應過度依賴這些陳述。

For a listing description of the risks and uncertainties associated with our business, please refer to the risk factors section of our latest periodic filing with the Securities and Exchange Commission. This conference call contains time sensitive information and is accurate only as it's live broadcast today, November 9, 2023.

有關與我們業務相關的風險和不確定性的清單描述，請參閱我們向美國證券交易委員會提交的最新定期文件中的風險因素部分。本次電話會議包含時間敏感訊息，僅在 2023 年 11 月 9 日今天直播時準確。

Hyperfine, Inc. disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. With that, I will turn the call over to Maria Sainz, President and Chief Executive Officer.

除法律要求外，Hyperfine, Inc. 不承擔任何更新或修改任何財務預測或前瞻性陳述的意圖或義務，無論是由於新資訊、未來事件或其他原因。接下來，我將把電話轉給總裁兼執行長瑪麗亞‧塞恩斯 (Maria Sainz)。

Good afternoon and thank you all for joining us. On the call with me today is our Chief Administrative Officer and Chief Financial Officer, Brett Hale. In the third quarter, we saw the benefits of our focus in the US and the realization of our new pricing model, resulting in an improvement in the financial profile of our business.

下午好，感謝大家加入我們。今天與我通話的是我們的首席行政官兼財務長 Brett Hale。在第三季度，我們看到了專注於美國的好處以及新定價模式的實現，從而改善了我們業務的財務狀況。

We achieved revenue of $2.3 million, flat compared to the same period last year and up 55% year to date. We sell fixed subsystems predominantly US direct sales, driving record average selling price and gross margin. As we have mentioned in the past, commercializing ultra-low-field MR brain imaging requires us to develop a new capital equipment imaging market.

我們實現了 230 萬美元的收入，與去年同期持平，但今年迄今成長了 55%。我們主要透過美國直銷方式銷售固定子系統，平均售價和毛利率創歷史新高。正如我們過去提到的，超低場磁振造影的商業化需要我們開發新的資本設備成像市場。

Our technology makes brain imaging possible at multiple sites of care from critical care units to neurology offices anytime a patient can benefit. We are still learning the dynamics of the selling cycle and advancing through many firms. With every deal being somewhat unique, considering our customers are early adopters of these new imaging paradigm.

我們的技術使從重症監護病房到神經科辦公室的多個護理場所的腦成像成為可能，患者可以隨時受益。我們仍在了解銷售週期的動態並透過許多公司取得進展。考慮到我們的客戶是這些新成像範例的早期採用者，每筆交易都有些獨特。

This involves adoption of new technology and new workflows. We also continue to closely manage our cash use with controlled spending while investing in our three strategic pillars; Innovation, clinical evidence and commercialization. Exiting the third quarter I'm very proud of the execution of the team, transforming our financial profile and laying a strong foundation for the future of our business.

這涉及採用新技術和新工作流程。我們也繼續透過控制支出來密切管理現金使用，同時投資於我們的三大策略支柱；創新、臨床證據和商業化。第三季結束時，我對團隊的執行力感到非常自豪，他們改變了我們的財務狀況，並為我們業務的未來奠定了堅實的基礎。

Innovation continues to be an area of great focus as we pursue development projects across all elements of the suite system. In addition to our many year-to-date improvements, we have a strong cadence of enhancements in hardware and AI powered software plans to further advance the image quality, clinical utility and application of ultra-low fields MRI.

當我們在套件系統的所有元素上尋求開發專案時，創新仍然是一個重點關注的領域。除了我們多年來迄今為止的改進之外，我們還在硬體和人工智慧驅動的軟體方面進行了強有力的增強，以進一步提高超低場 MRI 的影像品質、臨床實用性和應用。

On our last call, we mentioned our plan to launch another software upgrade by early 2024. Today, I am pleased to share that we have already received FDA clearance for this software update and plan to launch it before the end of the year a couple of months ahead of schedule. This is our eighth FDA-cleared since our initial system launch in 2020.

在上次電話會議上，我們提到計劃在 2024 年初啟動另一個軟體升級。今天，我很高興地告訴大家，我們已經獲得 FDA 對此軟體更新的許可，併計劃在今年年底前啟動它比計劃提前了幾個月。這是我們自 2020 年首次推出系統以來第八次獲得 FDA 批准。

It includes proprietary AI and deep learning algorithms in the DWI sequence adding significant value to the clinical utility of our platform. This expands our AID noising capabilities by incorporating advanced image post processing into the DWI sequence. The systems, other sequences, T1, T2 and FLAIR previously benefited from BCI's future.

它在 DWI 序列中包含專有的人工智慧和深度學習演算法，為我們平台的臨床實用性增加了重要價值。透過將先進的影像後處理融入 DWI 序列中，擴展了我們的 AID 雜訊能力。這些系統、其他序列、T1、T2 和 FLAIR 之前都受益於 BCI 的未來。

The noising enables a crisper image that potentially helps clinicians more accurately diagnose further treat and monitored patients undergoing brain imaging. As we move forward, we are continuously investing in improving our AI-powered imaging quality and usability, leveraging each imaging focused software release to further improve swoop system performance.

雜訊使影像更加清晰，可能有助於臨床醫生更準確地診斷、進一步治療和監測接受腦部影像的患者。隨著我們的前進，我們不斷投資於提高人工智慧驅動的成像品質和可用性，利用每個以成像為重點的軟體版本來進一步提高 swoop 系統效能。

As a reminder, the process of launching software updates is straightforward for our team and customers with most US commercial swoop systems operating at connected sites, with the new updates or don't download it remotely, we have the need for field team or technician intervention. We look forward to updating you on our innovation road map for 2024 on our next call.

提醒一下，啟動軟體更新的過程對我們的團隊和客戶來說非常簡單，大多數美國商業swoop 系統都在連接的站點上運行，如果有新的更新或不遠端下載，我們需要現場團隊或技術人員幹預。我們期待在下次電話會議上向您通報 2024 年創新路線圖的最新情況。

Now turning to clinical evidence I'd like to update you on the work we're doing on different studies across the breadth of current and future applications for our platform technology. We continue to collaborate with leading US and international institutions on multiple scientific research and clinical studies that support our current and future potential clinical use cases.

現在轉向臨床證據，我想向您介紹我們在平台技術當前和未來應用範圍內進行的不同研究的最新情況。我們繼續與美國和國際領先機構合作進行多項科學研究和臨床研究，以支援我們目前和未來潛在的臨床用例。

Relevant to our beachhead use case today, imaging patients in critical care I'm excited to share the data from the SAFE-MRI ECMO study was recently presented at the upheld meeting in Seoul, South Korea. The study evaluated the benefits of using portable MR brain imaging for monitoring patients on ECMO, which is advanced live support, highlighting its post operative Ischemic stroke detection capabilities compared to CT scan, especially in body ischemic injury early.

與我們今天的灘頭陣地用例相關的是，對重症監護患者進行成像，我很高興分享最近在韓國首爾舉行的會議上公佈的 SAFE-MRI ECMO 研究數據。該研究評估了使用便攜式MR 腦部影像監測ECMO（一種先進的即時支援）患者的益處，並強調了與CT 掃描相比，其術後缺血性中風檢測能力，特別是在早期身體缺血性損傷中。

The study further underscores the role of MR based Nuro imaging in acute brain injury detection and the potential for allowing improvement in neurological outcomes. In stroke we are pleased with the pace of involvement and physician excitement in our action PMR study, a multi-center evaluation to assess the use of swoop system in detecting acute ischemic stroke. We remain bullish about this opportunity and look forward to sharing updates in the coming quarters.

該研究進一步強調了基於 MR 的 Nuro 成像在急性腦損傷檢測中的作用以及改善神經系統結果的潛力。在中風方面，我們對行動 PMR 研究的參與速度和醫生的興奮程度感到滿意，這是一項多中心評估，旨在評估 swoop 系統在檢測急性缺血性中風中的使用情況。我們仍然看好這個機會，並期待在未來幾季分享最新消息。

Looking further ahead, I wanted to touch on the large new opportunity for the MRI industry in the treatment of all segments. We believe the portable swoop system can offer a highly differentiated, cost-effective and accessible solution f or this new use case.

展望未來，我想談談 MRI 產業在所有細分市場治療方面的巨大新機會。我們相信便攜式 swoop 系統可以為此新用例提供高度差異化、經濟高效且易於使用的解決方案。

We have committed to conducting a clinical feasibility study led by a tube system, key opinion leader who also has a passion for Alzheimer's. The swoop system will be placed in the infusion center workflow for the feasibility study, rendering the care navigation of the patient more efficient. We are preparing to begin enrollment in the next couple of months. We have also appointed an Alzheimer's advisory committee comprised of [top] leaders to help shape our efforts in this area.

我們致力於開展一項由同樣對阿茲海默症充滿熱情的關鍵意見領袖管系統所領導的臨床可行性研究。 swoop系統將被放置在輸液中心工作流程中進行可行性研究，使病患的護理導航更有效率。我們準備在接下來的幾個月內開始招生。我們還任命了一個由[高層]領導人組成的阿茲海默症諮詢委員會，以幫助制定我們在這一領域的工作。

Turning to commercialization. As our US commercial team gain tenure and experience selling the swoop system, they're driving a broader and more robust deal pipeline quarter-after-quarter. US deals dominated our revenue makeup in the quarter, including the completion of our multi-system sale to the Barnes Jewish Health Care System We have previously announced.

轉向商業化。隨著我們的美國商業團隊獲得銷售 swoop 系統的任期和經驗，他們正在逐季推動更廣泛、更穩健的交易管道。美國交易主導了我們本季的收入組成，包括我們先前宣布的完成向巴恩斯猶太醫療保健系統的多系統銷售。

As we have mentioned before, our sales cycle is six to nine months. We implemented a new pricing strategy in early 2023. The heavy US mix we drove in the third quarter, coupled with the realization of our higher US pricing translated into a record overall ASP [underscored] gross margin.

正如我們之前提到的，我們的銷售週期是六到九個月。我們在 2023 年初實施了新的定價策略。我們在第三季推出的大量美國產品組合，加上美國定價較高的實現，轉化為創紀錄的整體 ASP [強調]毛利率。

We are in the early days of building this new market of all Carlo field, brain engine, we are still navigating and understanding the dynamics of the sales cycle and often space, multiple reviews and approvals from clinical new technology and more safety, legal, IT and administrative constituents, you need to reach account resulting in time line variability.

我們正處於建立全卡羅領域腦引擎這個新市場的早期階段，我們仍在探索和了解銷售週期的動態以及經常空間、來自臨床新技術和更多安全、合法、IT的多重審查和批准和行政部門，您需要聯絡帳戶，從而導致時間軸的變化。

As I mentioned in our last call, we've recently iterated the makeup of our US field force and have established three dedicated teams focused on selling, implementation and utilization. We are pleased with this new structure and hope to drive greater sales volumes and a strong reference site as our teams mature in their roles.

正如我在上次電話會議中提到的，我們最近迭代了美國現場部隊的組成，並建立了三個專門的團隊，專注於銷售、實施和利用。我們對這種新結構感到滿意，並希望隨著我們的團隊在角色上的成熟，能夠推動更大的銷售和強大的參考網站。

As I complete my 1st year as the CEO role at Hyperfine, I am very pleased to report on the increasing interest in our technology across many different institutions. The strong positive feedback on our imagers and clinical utility and the record number of image reviews and demos that we are now running. These are all encouraging indicators strengthening our commercial foundation.

在我擔任 Hyperfine 執行長的第一年中，我很高興地向大家報告，許多不同機構對我們的技術越來越感興趣。對我們的成像儀和臨床實用性的強烈積極反饋以及我們現在正在運行的創紀錄數量的圖像審查和演示。這些都是令人鼓舞的指標，加強了我們的商業基礎。

Before I turn the line over to Brett I'm proud of the progress we're making and the continued focus we have on spending discipline on gross margin. Our focus remains on operating lean while investing in innovation clinical evidence and commercialization, we continue to see a cash runway for the business through 2025. I will now turn the call over to Brett to review our third quarter performance and discuss the financial outlook in greater detail.

在我把電話轉給布雷特之前，我對我們所取得的進展以及我們對毛利率支出紀律的持續關注感到自豪。我們的重點仍然是精益運營，同時投資於創新、臨床證據和商業化，我們繼續看到該業務到2025 年的現金跑道。我現在將把電話轉給Brett，回顧我們第三季度的業績，並討論更廣泛的財務前景。細節。

Thank you, Maria. Turning to our financial results for the third quarter of 2023. Revenue for the quarter ended September 30th, 2023 was $2.3 million, flat compared to the third quarter of 2022. Year-to-date, we've generated $8.3 million of revenue, up 55% from the first nine months of 2022.

謝謝你，瑪麗亞。轉向 2023 年第三季的財務業績。截至 2023 年 9 月 30 日的季度收入為 230 萬美元，與 2022 年第三季持平。年初至今，我們已創造了 830 萬美元的收入，同比增長2022 年前9 個月增長55%。

Gross profit for the third quarter of 2023 was $1.1 million compared to $0.7 million in the third quarter of 2022 and reflecting a record 48% gross margin. Year to date, we have a 45% gross margin, up 34%-points from the 11% for the first nine months of 2022.

2023 年第三季的毛利為 110 萬美元，而 2022 年第三季為 70 萬美元，毛利率達到創紀錄的 48%。今年迄今為止，我們的毛利率為 45%，比 2022 年前 9 個月的 11% 增加了 34 個百分點。

R&D expenses for the third quarter of 2023 were $5.7 million compared to $7.3 million in the third quarter of 2022. Sales, general and administrative expenses for the third quarter of 2023 were $7.1 million compared to $6.6 million in the third quarter of 2022. Year to date, total OpEx of $40.2 million is down 34% from $60.9 million in the first nine months of 2022.

2023 年第三季的研發費用為570 萬美元，而2022 年第三季為730 萬美元。2023 年第三季的銷售、一般及管理費用為710 萬美元，而2022 年第三季為660 萬美元。截至目前，營運支出總額為 4,020 萬美元，比 2022 年前 9 個月的 6,090 萬美元下降了 34%。

Net loss for the third quarter was $10.8 million, equating to a net loss of $0.15 per share as compared to a net loss of $13.2 million or a net loss of $0.19 per share for the same period of the prior year. Year to date, net loss of $33.6 million is down 44% from 60.1 million in the first nine months of 2022.

第三季淨虧損為1,080萬美元，相當於每股淨虧損0.15美元，而上年同期淨虧損為1,320萬美元，每股淨虧損0.19美元。今年迄今為止，淨虧損為 3,360 萬美元，比 2022 年前 9 個月的 6,010 萬美元下降了 44%。

Our cash burn in the third quarter was $8.5 million. And as of September 30, 2023, we had $85.4 million in cash and cash equivalents on our balance sheet. Year to date, our cash burn of $32 million, down 43% from $56 million in the first nine months of 2022.

第三季我們的現金消耗為 850 萬美元。截至 2023 年 9 月 30 日，我們的資產負債表上有 8,540 萬美元的現金和現金等價物。今年迄今為止，我們的現金消耗為 3,200 萬美元，比 2022 年前 9 個月的 5,600 萬美元下降了 43%。

Turning to our 2023 outlook, we are narrowing our full year revenue expectations to a range of $11 million to $13 million. Based on our early Q4 closings and the progress in our pipeline. Looking at gross margin for the year, we are narrowing our range to 44% to 46% as we grow and realize higher average swoop system pricing.

談到 2023 年的展望，我們將全年營收預期縮小至 1,100 萬美元至 1,300 萬美元。基於我們第四季早期的結帳情況和管道的進展。就今年的毛利率而言，隨著我們的發展並實現更高的平均 swoop 系統定價，我們將範圍縮小到 44% 至 46%。

We are very pleased to be driving healthy margins in our business, even at small scale. And lastly, we are narrowing our total cash burn expectations to $41 million to $44 million for the full year 2023. This incorporates an expectations for continued investment in R&D and substantially streamlined investments in SG&A versus history.

我們很高興能夠在我們的業務中推動健康的利潤率，即使是小規模的業務。最後，我們將 2023 年全年的現金消耗總額預期縮小至 4,100 萬至 4,400 萬美元。這包括對研發的持續投資以及與歷史相比大幅精簡的 SG&A 投資的預期。

While we maintain customer facing resources to continue to drive adoption a growth. We will continue to focus on our three strategic pillars and maintain spending discipline, maintaining enough cash to fund the business through 2025. We are excited about the momentum we are building for the remainder of the year and beyond, and we are pleased to have the cash and flexibility to invest in the right areas for continued swoop system adoption. At this point, I'd like to turn the call back to Maria for closing comments.

同時我們保留面向客戶的資源，以繼續推動採用率的成長。我們將繼續專注於我們的三大策略支柱，並保持支出紀律，保持足夠的現金為業務提供資金到 2025 年。我們對今年剩餘時間及以後所建立的勢頭感到興奮，我們很高興能夠現金和靈活性投資於正確的領域，以繼續採用swoop 系統。此時，我想將電話轉回瑪麗亞以徵求結束意見。

Thank you, Brett. I'm proud of the progress the Hyperfine team has made so far this year, and I remain very optimistic as to what they see and deliver. With that, I want to thank you for your time and open the line up for questions.

謝謝你，布雷特。我對 Hyperfine 團隊今年迄今所取得的進展感到自豪，我對他們所看到和交付的成果仍然非常樂觀。在此，我要感謝您抽空提問。

(Operator Instructions) Neil Chatterji with B. Riley.

（操作員說明）Neil Chatterji 和 B. Riley。

Hey, guys. Thanks for taking the questions. Good afternoon. Can you hear me, okay.

大家好。感謝您提出問題。午安.你聽得到我說話嗎？

Good afternoon. Yeah, I can hear you fine.

午安.是的，我聽得很清楚。

Great. Perfect. Just starting off some on the sales funnel. Just curious if you have any more color on how that's progressing as we kind of get close to the exiting the year and getting into 2024. And then just with the latest software update, how might that help with the funnel and future uptake?

偉大的。完美的。剛開始銷售漏斗中的一些工作。只是好奇，隨著我們即將結束這一年並進入 2024 年，您是否對進展情況有更多的了解。然後，透過最新的軟體更新，這對漏斗和未來的吸收有何幫助？

Sure. So we just said we are feeling positive about the early traction with the breadth of the pipeline. We do have more tenured and more experienced reps every quarter that we go by, and that continues to drive sort of the good traction and progress in our pipeline. We have announced the clearance of the new software but we haven't yet launched it.

當然。所以我們剛剛說過，我們對管道的廣泛性的早期牽引力感到積極。每個季度我們確實都有更多的終身任職和經驗更豐富的代表，這繼續推動我們管道的良好牽引力和進展。我們已經宣布新軟體已獲許可，但尚未推出。

We're taking a little bit of a different stance at this time, which we're doing an early access program with few customers here this week to make sure we get all of the feedback so that we can launch with more testimonials and more meat on the bone. So you should expect the relief for our customers sort of very early into the new year.

我們現在採取了一些不同的立場，本週我們正在與很少的客戶一起進行搶先體驗計劃，以確保我們獲得所有反饋，以便我們可以推出更多推薦和更多內容在骨頭上。因此，您應該期待我們的客戶在新年伊始就能得到緩解。

So from an innovation perspective, that is going to really drive nice thing because we said there is an enhancement in DWI which is really the king and queen sequence, especially in the stroke application, but it also has a nice set of features around usability that are that I think are going to be well appreciated by existing customers to continue to reinforce usage and buy new customers that are contemplating acquiring the system.

因此，從創新的角度來看，這將真正推動好事，因為我們說過DWI 有所增強，這確實是國王和王后序列，特別是在筆畫應用程式中，但它還具有一組圍繞可用性的很好的功能，我認為現有客戶將非常讚賞繼續加強使用併購買正在考慮購買該系統的新客戶。

Great. Thanks for that. And then just on also Alzheimer's, just any update on kind of the progress there? I think you were planning for some early feasibility studies returns through [these release]. Yeah any update there and any updated thoughts on that potential opportunity?

偉大的。感謝那。還有阿茲海默症，有沒有進展的最新狀況？我認為您正在計劃透過[這些版本]獲得一些早期可行性研究回報。是的，有什麼更新以及對潛在機會的任何最新想法嗎？

Sure. So we continue to be really bullish about that because we believe access and ease of getting these discounts is going to really drive a lot of the efficiency and how those patients are going to navigate their way between neurology, infusion sites and imaging location. And we are even more pleased that what we're doing is really following the very strong interest that has been formulated to us by some of the physicians that know our system and what it can do.

當然。因此，我們仍然非常看好這一點，因為我們相信，獲得這些折扣的機會和便利性將真正提高效率，以及這些患者如何在神經科、輸液部位和成像位置之間導航。更令我們高興的是，我們正在做的事情確實是遵循了一些了解我們的系統及其功能的醫生向我們提出的非常強烈的興趣。

So we're going to start early feasibility by the end of this year with one of those swoop aficionados or KOL's, that is also someone very involved in Alzheimer's treatments. And as I said in the prepared remarks, what we're doing is trying to place our swoop system in the workflow of the infusion of the drug to make it a lot more convenient for the patient. And the idea is going to be how this really helps assess the risk for these patients. But early feasibility is something that we expect to start in the next couple of months.

因此，我們將在今年年底前與其中一位狂熱愛好者或 KOL 開始早期可行性研究，他們也是積極參與阿茲海默症治療的人。正如我在準備好的演講中所說，我們正在做的就是嘗試將我們的 swoop 系統放入藥物輸注的工作流程中，以使患者更加方便。這個想法將是如何真正幫助評估這些患者的風險。但我們預計在未來幾個月內開始早期可行性研究。

Great. That's it for me. I'll hop back in queue. Thanks.

偉大的。對我來說就是這樣。我會跳回隊列。謝謝。

Sure. Thank you.

當然。謝謝。

Thank you. There are no further questions at this time. I'd like to turn the call over to Maria Sainz for closing remarks.

謝謝。目前沒有其他問題。我想將電話轉給瑪麗亞·塞恩斯（Maria Sainz）做結束語。

Well, thank you for your interest this afternoon, and we look forward to keeping you informed in future calls.

好的，感謝您今天下午的關注，我們期待在以後的電話中向您通報情況。

Thank you for your participation. And this does conclude the program, and you may now disconnect. Everyone, have a great day.

感謝您的參與。這確實結束了程序，您現在可以斷開連接。大家，祝你有美好的一天。